Urogen Pharma (URGN) Stock Price, News & Analysis

Company Overview

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer. Jelmyto represents the first FDA-approved therapy for this indication, offering a minimally invasive, kidney-sparing alternative to surgery. Beyond Jelmyto, UroGen’s pipeline includes UGN-102, an investigational mitomycin solution under study for interstitial cystitis/bladder pain syndrome, and earlier-stage programs targeting other urologic and ophthalmic conditions leveraging the RTGel platform.

UroGen markets its products primarily in the United States and is pursuing regulatory submissions in Europe and other global regions. The company’s management team is led by Co-Founder and Chief Executive Officer Tomer Kariv, supported by Chief Operating Officer Vas Narasimhan and Chief Medical Officer Philip Isaacs, among others. UroGen collaborates with key opinion leaders in urology to advance its clinical programs and expand patient access to novel in-office therapies.

Key Stats

• Today's Range: $43.45 to $45.63
• 50-Day Range: $34.38 to $50.29
• 52-Week Range: $15.86 to $50.81
• Volume: 194,669 shs
• Average Volume: 804,728 shs
• Market Capitalization: $2.21 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $50.38
• Consensus Rating: Moderate Buy

Urogen Pharma Stock Analysis - MarketRank™

Urogen Pharma scored higher than 55% of companies evaluated by MarketBeat, and ranked 381st out of 914 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Urogen Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 7 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Urogen Pharma has a consensus price target of $50.38, representing about 15.3% upside from its current price of $43.70.

Amount of Analyst Coverage

Urogen Pharma has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Urogen Pharma are expected to grow in the coming year, from ($0.20) to $3.49 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Urogen Pharma is -22.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Urogen Pharma is -22.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.00% of the float of Urogen Pharma has been sold short.

Short Interest Ratio / Days to Cover

Urogen Pharma has a short interest ratio ("days to cover") of 4.8.

Change versus previous month

Short interest in Urogen Pharma has recently increased by 11.58%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Urogen Pharma does not currently pay a dividend.

Dividend Growth

Urogen Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 4.1 / 5
• News Sentiment: 1.54

News Sentiment

Urogen Pharma has a news sentiment score of 1.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Urogen Pharma this week, compared to 4 articles on an average week.

Search Interest

Only 3 people have searched for URGN on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

MarketBeat Follows

9 people have added Urogen Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Urogen Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,747,513.00 in company stock.

Percentage Held by Insiders

4.80% of the stock of Urogen Pharma is held by insiders.

Percentage Held by Institutions

91.29% of the stock of Urogen Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 9/03/2026
• Wells Fargo 21st Annual Healthcare Conference: 9/09/2026
• 12th Annual Cantor Fitzgerald Global Healthcare Conference: 9/10/2026
• H.C. Wainwright 28th Annual Global Investment Conference: 9/15/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:URGN
• CIK: 1668243
• Web: www.urogen.com
• Phone: (646) 768-9780
• Fax: N/A
• Employees: 200
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Urogen Pharma: $50.38
• High Price Target: $75.00
• Low Price Target: $33.00
• Potential Upside/Downside: +11.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.98)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$153.49 million
• Net Margins: -51.73%
• Pretax Margin: -51.98%
• Return on Equity: N/A
• Return on Assets: -43.79%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.80
• Quick Ratio: 3.41

Sales & Book Value

• Annual Sales: $109.79 million
• Price / Sales: 20.15
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.71) per share
• Price / Book: -16.70

Miscellaneous

• Outstanding Shares: 48,880,000
• Free Float: 46,535,000
• Market Cap: $2.21 billion
• Optionable: Optionable
• Beta: 1.57